- Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer.
- CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer.
- With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel.
- Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.
For further details see:
Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies